A new immunotherapy called GTB-5550 targeting B7-H3 on cancer cells has received FDA clearance for its first human trial (expected to start in the first half of 2026), offering fresh hope particularly for advanced prostate cancer patients exhausted by standard treatments. GTB-5550 is a TriKE molecule that binds natural killer (NK) cells from the immune […]
The WOLVERINE study is a major analysis combining patient data from seven phase 2 trials, published in The Lancet Oncology. It looked at 574 men with oligometastatic prostate cancer (meaning up to five spots of cancer spread), mostly to bones or lymph nodes. Six of those trials (472 men) directly compared adding metastasis-directed therapy (MDT) […]
The first-in-human phase 1 trial of OP-3136, a novel orally bioavailable KAT6A/B inhibitor for solid tumors, started recruiting, with the prostate cancer cohort focusing on men with metastatic castration-resistant prostate cancer (mCRPC). This represents a significant expansion of OP-3136 beyond its initial focus on estrogen receptor-positive breast cancer, following encouraging preclinical data presented at AACR […]
The Alliance A222001 study, published in the Journal of Clinical Oncology in January 2026, found that oxybutynin, a drug typically used to treat overactive bladder, significantly reduces hot flashes in men receiving androgen-deprivation therapy (ADT), with improvements occurring within the first week of treatment and sustained throughout the study period. The findings could reshape how […]
The JASPER trial is a phase 1/2 study launching from the University of Michigan, takes a fundamentally different approach to castration-resistant prostate cancer by targeting the molecular machinery driving cancer plasticity from the start: the JAK/STAT inflammatory signaling axis. Understanding why this strategy makes biological sense requires stepping into what we now know about how […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Another week of fighting against our common enemy. And another wave of new weapons.! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. […]
The ANDROMEDA phase 2 trial represents an advancement in managing recurrent oligometastatic prostate cancer by directly pitting alpha-emitting 225Ac-PSMA-617 against the established beta-emitting 177Lu-PSMA-617 (Pluvicto), both combined with stereotactic body radiotherapy (SBRT). This head-to-head comparison stems from the need to address limitations in current therapies for patients whose cancer returns in 1-5 detectable spots on […]
Imagine you have a long string of DNA code, a million letters long. A new AI tool called AlphaGenome reads that code and predicts exactly what it does. It tells you how active genes are, how DNA folds open or closed, where proteins stick to it, and even how far-apart parts of DNA touch each […]
A promising study published this month in Science Advances introduces a promising “neuroimmunotherapy” nanocarrier called LipoNCs@pGSDMB, designed precisely for bone metastases like those in prostate cancer. This tiny, smart drug delivery system activates only in the high-oxidative-stress environment of bone tumors, fusing directly with cancer cell membranes to release its payload straight into the cell’s […]
SHR-A1921, also known as tizetatug rezetecan, represents a significant advancement in targeted cancer therapeutics, specifically designed to exploit TROP2 overexpression in aggressive malignancies including prostate cancer. This novel antibody-drug conjugate (ADC) has demonstrated compelling preclinical activity in prostate cancer models and encouraging early clinical results across multiple solid tumors, positioning it as a potential therapeutic […]